Sydney - Thursday - May 31: (RWE Australian Business News) - Neuren Pharmaceuticals Ltd (ASX:NEU) says the first patient has entered the Phase 3 clinical trial of its lead compound, Glypromate, to reduce cognitive impairment in patients following cardiac surgery.
